

CHREV 209

PACKINGS AND STATIONARY PHASES IN PREPARATIVE COLUMN LIQUID CHROMATOGRAPHY*

K. K. UNGER* and R. JANZEN

Institut für Anorganische Chemie und Analytische Chemie, Johannes Gutenberg-Universität, 6500 Mainz (FRG)

(First received February 14th, 1986, revised manuscript received June 10th, 1986)

CONTENTS

1 Introduction	228
2. Role of packings and stationary phases in the optimization of loadability and throughput	228
3 Criteria for the efficient operation of packings and phase systems in preparative chromatography	230
3.1. Bed stability and flow resistance	230
3.2. Chemical resistance and purity	231
3.3. Solute accessibility	231
3.4. Mass recovery and bioactivity	231
3.5. Fouling	232
3.6. Regeneration	232
3.7. Cost	232
4 Relevance of physical and chemical structure parameters of packings in preparative chromatography	233
4.1. Physical structure parameters	233
4.1.1. Particle shape	233
4.1.2. Particle size and size distribution	233
4.1.3. Specific pore volume, v_p	233
4.1.4. Specific surface area, a_s	233
4.1.5. Pore diameter, p_d	234
4.2. Chemical structure parameters	235
5 Survey of commercial packings in preparative and process-scale chromatography	236
5.1. Adsorbents	236
5.2. Size exclusion packings	243
5.3. Ion-exchange packings	243
5.4. Affinity packings	243
6 Key aspects in choosing a phase system for preparative and process chromatography	243
6.1. Size exclusion chromatography	261
6.2. Adsorption chromatography	261
6.3. Ion-exchange chromatography	262
6.4. Affinity chromatography	262
7 Future prospects	262
8 List of suppliers	262
9 Summary	263
References	263

* Presented at the First International Symposium on Preparative and Up-scale Liquid Chromatography, Paris, 15-17th January, 1986

1 INTRODUCTION

The rapid development of biotechnology and the requirements placed on the purity of biopharmaceutical products have drastically increased the importance of preparative and scaled-up column liquid chromatography in purification and isolation processes. The substances concerned include complex organic molecules, *e.g.*, antibiotics, and proteins of a molecular mass above 10 kdaltons, *e.g.*, enzymes and monoclonal antibodies of concentrations between 0.1 g dm^{-3} and $1 \mu\text{g dm}^{-3}$ in the starting mixture. Particular emphasis has been placed on the isolation of expensive materials with selling prices exceeding US \$1000 kg⁻¹.

In order to purify the product as cost-effectively as possible, methods are sought that provide a high specificity and a high recovery. One of the key aspects currently influencing the effectiveness of column liquid chromatographic techniques relates to the evaluation of improved and tailored support materials, capable of highly selective separations and flexible with respect to process optimization. Although the theoretical concepts of preparative chromatography provide clear directives regarding the support properties, practical implications, *e.g.*, fouling, regeneration, stability and purity, are equally important.

This paper attempts to analyse the decisive features of supports that control the target quantities of the purification processes. It provides an up-to-date survey of the media applied in the various modes of column liquid chromatography and discusses general aspects concerning the choice of appropriate phase systems.

2 ROLE OF PACKINGS AND STATIONARY PHASES IN THE OPTIMIZATION OF LOADABILITY AND THROUGHPUT

The established relationships between loadability, throughput, maximum product of resolution and sample input, and the chromatographic process parameters provide a rational basis for discussing the effects of the support and stationary phase properties. The performance (with respect to the specified purity and yield of a desired product) of an isolation process is determined by the loadability and the throughput^{1,2}. Loadability, defined as the maximum sample input, $Q_i(\max)$, corresponding to certain requirements with respect to resolution and peak shape, is given by

$$Q_i(\max) = 2\pi^{\frac{1}{2}} A \varepsilon_m L (C_{i,m})^{\max} (1 + k'_i) N_i^{-\frac{1}{2}} \quad (1)$$

where A is the column cross-section, ε_m the porosity of the chromatographic bed, L the column length, $(C_{i,m})^{\max}$ the maximum $C_{i,m}$ value of the elution profile at the column outlet, k' the capacity factor of the solute i and N_i the plate number of the column.

Eqn. 1 implies that the maximum sample mass to be injected depends on the maximum solute concentration in the mobile phase at the column outlet. $(C_{i,m})^{\max}$ was shown to be a primary function of the shape of the solute isotherm, and hence controlled by the type of phase system employed^{1,2}. It is also evident from eqn. 1 that $Q_i(\max)$ increases with increasing solute capacity factor and with decreasing plate number of the column. Studies by De Jong and co-workers¹ have demonstrated that the specific loadability of a given column, expressed as sample mass injected per

gram of packing, increases with decreasing plate number; a so-called loadability borderline was established where the column dispersion played a negligible role and the elution profile was dictated by the isotherm non-linearity broadening¹.

The throughput, T_i , defined as the mass of product isolated per unit time at a desired purity, is given by

$$T_i = Q_i(\max)/t_{R_i} \quad (2)$$

where t_{R_i} is the retention time of solute i

When the mass of product isolated equals 95% of $Q_i(\max)$, assuming a solute sampling interval of $4\sigma_n$ seconds, eqn. 2 becomes

$$T_i = f_v \cdot 2\pi^{\frac{1}{2}} \cdot 0.95 (C_{i,m})^{\max} \cdot \frac{1 + k'_i}{1 + k'_l} \cdot N_i^{-\frac{1}{2}} \quad (3)$$

where f_v is the volume flow-rate, k'_i and k'_l are the capacity factors of solute i and the last eluting compound l and N_i is the required plate number.

On optimizing the throughput $[(C_{i,m})^{\max}]$, the solute capacity factor and the plate number of the column play decisive roles in addition to the eluent flow-rate. Columns packed with large particles and operated at high flow-rates appear to favour a high throughput.

Whereas in analytical separations the aim is the optimum resolution of an extremely small feed volume, the main concern in preparative isolation is to obtain a maximum of the product of the chromatographic resolution, R_{ji} , and the sample input, Q_i ³.

The sample input, Q_i , is equal to

$$Q_i = C_i^0 v_0 \quad (4)$$

where C_i^0 is the initial concentration of solute i and v_0 the feed volume. Assuming

$$v_0^2 \gg (1 + k'_i)^2 / (k'_l N_i) \quad (5)$$

the product $R_{ji} Q_i$ approaches the limiting value

$$\lim R_{ji} Q_i = (k'_j - k'_i) v_m \cdot \frac{C_i^0}{\psi} \quad (6)$$

where k'_i and k'_j are the capacity factors of the solutes i and j (k'_j being larger than k'_i), v_m is the volume of mobile phase in the column and ψ is a factor characterizing the shape of the input peak.

Eqn. 6 implies that where there is a large difference between the peak maxima of solutes i and j , the concentration of the sample can be increased at a large feed volume to maximize $R_{ji} Q_i$. The peak positions of solutes i and j with column over-loading are again controlled by the shape of the isotherm.

In conclusion, highly selective phase systems are essential in preparative work in order to achieve a high loadability and throughput.

3. CRITERIA FOR THE EFFICIENT OPERATION OF PACKINGS AND PHASE SYSTEMS IN PREPARATIVE CHROMATOGRAPHY

The equations presented in the preceding section provide fundamental guidelines for exploiting simple preparative separation schemes. In practice, sample mixtures containing solutes at various concentration ratios have been applied in binary and ternary solvent systems in both isocratic and gradient elution modes. Thus, a reliable estimate of loadability should be based on data taken from isotherms of multicomponent solutions rather than from isotherms of single solutes⁴. When the solutes to be purified differ in their polarity, the peak profiles at high loading can be disturbed by displacement phenomena; these might cause a loss or improvement in resolution at increased loadability⁵. Peak profiles have also been known to be affected by the mode of injection, *i.e.*, by the design of the injection device^{1,2,6,7}. The successful application of packings in practice depends on a series of criteria that are not included in the basic equations and hence will be discussed below.

3.1. Bed stability and flow resistance

Bed stability is a necessary precondition for high-resolution separations. In preparative chromatography, the columns are longer and wider than in routine analytical work, packed with larger particles and operated at higher flow-rates. The relationship between the linear eluent velocity, u , and the column pressure drop, Δp , is given by

$$u = \frac{\Delta p K_0}{\eta L} = \frac{\Delta p d_p^2}{\Phi L \Phi} \quad (7)$$

where K_0 is the chromatographic permeability, η the eluent viscosity, L the column length, d_p the particle diameter of the packing and Φ the flow resistance factor⁸. As a result, a linear relationship holds between the eluent flow-rate and the column pressure drop. Semi-rigid and soft gels, however, deviate from the expected linearity owing to their compressibility.

One way to overcome possible bed compression of semi-rigid gels is to use stacked columns⁹. Devices for adjusting the bed height of preparative columns have also been constructed. Shrinkage and/or swelling of the column bed may also occur with soft and semi-rigid organic gels, depending on the degree of cross-linking and on the eluent composition. With small-bore columns the bed is supported by the column walls, whereas with large-bore columns this stabilizing influence is negligible. Thus, distinctly different flow pressure characteristics are obtained for columns varying in diameter, under otherwise constant conditions. By increasing the column length the weight of the packing is also increased, which concurrently raises the hydrostatic pressure. Therefore, when employing large bed heights the particles should possess sufficiently high mechanical stability. Another phenomenon that must be taken into account is the abrasive action of the flow on the particles; this generates fines which

then block the column outlet. In order to avoid all of these problems, spherical particles are to be preferred to irregularly shaped particles, as has been the practice in the operation of fixed-bed catalytic reactors and large-scale adsorption columns. Spherical particles with adequate particle uniformity and acceptable size distribution provide the most dense and stable column bed.

3.2. Chemical resistance and purity

None of the packings in column liquid chromatography behaves in a totally inert manner towards the eluent and the solutes. Rather, they exhibit a limited lifetime, associated with degradation by dissolution, chemical surface reactions, ageing and other processes. On using bonded silicas, traces of organosilicon compounds might be released from the packing when the bonding reaction has not been carried out properly, or conditions might be chosen that favour a cleavage of bonded groups. Monomers might dissolve from polymer gels. All these phenomena will impair the purity of the products to be separated, presenting a serious problem in the isolation of biopharmaceutical products. The elimination of traces of impurities by subsequent purification procedures is extremely time consuming and costly. For this reason, the utmost care is advised when choosing the packing material.

3.3. Solute accessibility

This criterion is of lesser relevance in the separation of low-molecular-weight compounds; however, it is highly important in the isolation of large molecules, particularly proteins and enzymes. A series of studies (for comparison see ref. 10) demonstrated that a major part of the internal surface of a packing is not fully utilized for the separation of large molecules by interaction chromatography; this was attributed to limited surface access. In other words, the main concern is to achieve a surface that is fully accessible to a solute of defined size. This finding led to the development and propagation of so-called wide-pore materials for the separation of biopolymers by column liquid chromatography. It was also shown that even a sufficiently large external surface of small non-porous particles is adequate to achieve an excellent resolution of biopolymers, *e.g.*, by reversed-phase gradient HPLC¹⁰. These concepts have found widespread application in the continuing design of appropriate macro-porous packings.

3.4. Mass recovery and bioactivity

Because of the irreversible adsorption of solutes in chromatographic operation, there is bound to be a certain loss of mass. Hence, a complete mass recovery of the solute in the preparative phase system in operation is required for the complete isolation of the product. There are various methods, and the application of a radio-labelled solute is the most reliable for an assessment of mass recovery. In the isolation of biologically active solutes, the aim is to collect the product without any loss in its bioactivity, *e.g.*, enzymatic activity. Partial unfolding or denaturation of a biopolymer in chromatographic processes is known to be attributable to eluent-mediated and/or surface-induced dynamic effects¹¹. The extent of conformational changes of

a given solute, *e.g.*, a protein or enzyme, is also observed to be a function of the residence time in a given column. Therefore, maintenance of the biological activity of a solute is specifically dependent on the phase system applied and on the operating conditions.

3.5. *Fouling*

Fouling is a well known phenomenon in the operation of heterogeneous industrial catalysts. It is understood to involve deposition of certain by-products or dust, impairing the catalytic activity and/or selectivity. Coke formation on catalysts in cracking reactions of hydrocarbons is one example. Fouling is also caused by microparticulate matter (fines introduced by the feed). In chromatographic terms, fouling of the surface might take place through preferential adsorption or reaction of active components of the sample mixture. Colloidal fines or particulates from hydrolysates might be deposited in the pores or between the interstices of the packing particles, mainly at the column top, and cause significant changes in column permeability. In the separation of biologically active substances, another type of fouling is microbial contamination, which can be prevented by mobile phase additives and other precautionary measures¹²

3.6. *Regeneration*¹²

After a period of time, when the resolution or other parameters are observed to decline noticeably, the column should be regenerated to restore its quasi-original state. Regeneration is achieved by washing the column with a solution or solvent of high solvent strength relative to the packing. Often a series of solvents are applied, depending on the compatibility with the eluent. In this way, soluble deposits and impurities adsorbed by the packing are displaced, and the column is returned to a quasi-virgin state. For silicas and their bonded phases, polar or non-polar solvents are applied. Polymer gels are preferably washed with acidic or alkaline solutions. The time required to regenerate a column is dependent on the particle size and the pore size. Packings consisting of large particles have longer diffusion path lengths than microparticles, at constant pore size, eluent and given solute. At constant particle size, diffusion is also a function of the pore size. Packings with small pores require a more extensive period of regeneration than large pore packings.

3.7. *Cost*

Packings for use in large-scale chromatography should be available at an economical price. This price is determined by the particle shape, the particle size and size distribution, the degree of purity, the extent of surface modification, etc. Spherical particles are about five times more expensive than angular particles; this is due to the specific technology applied for beading. With decreasing average particle size, size classification processes are increasingly reflected by the cost. This is illustrated by the price difference (by a factor of 10) between 10- and 100- μm particles. Narrow cuts are more difficult to produce than those with a broad particle size distribution. Specially purified chemicals must be employed for the manufacture of highly pure

packings, differing from the usual process with technical reagents. A high purity is seldom achieved by extraction of technical-grade packings.

Chemical bonding of adsorbents and supports raises the price by a factor of two for common silanization or other reactions. Specific bonding reagents, such as for the synthesis of chiral and affinity packings, further increase the price.

4 RELEVANCE OF PHYSICAL AND CHEMICAL STRUCTURE PARAMETERS OF PACKINGS IN PREPARATIVE CHROMATOGRAPHY

As chromatographers take no part in the manufacture of packings, they ought to be able to judge the suitability of a packing for a given separation on the basis of the specifications given by the manufacturer. We shall first discuss the physical structure parameters as they are broadly applicable independent of the mode of LC, whereas chemical structure parameters are specific to the type of phase system applied and the solute to be purified.

4.1. Physical structure parameters

Table 1 lists the physical structure parameters of packings, together with their definitions^{13,14}.

4.1.1. Particle shape

Beaded packings of uniform shape are preferred to angular packings in order to achieve a highly dense and stable column bed, thereby avoiding the abrasion that causes fines, and helping to maintain a high mechanical stability in large columns. These merits must, however, be paid for by the higher price of the spherical packing.

4.1.2. Particle size and size distribution

The average particle diameter of packings in preparative and process chromatography ranges from 20 to 200 μm . Packings with $d_p < 20 \mu\text{m}$ are essentially applicable in analytical HPLC and are employed when high plate numbers are required. Packings with d_p between 40 and 60 μm provide a good compromise between column pressure drop, Δp , plate number, N , and analysis time, t_c . For optimization of resolution and efficiency in HPLC, see refs. 15 and 5. A narrow particle size distribution with a $d_{p_{90}}/d_{p_{10}}$ ratio of 1.5–2.0 of the cumulative distribution is adequate for the generation of a stable and efficient column.

4.1.3. Specific pore volume, v_p

Except for the size exclusion mode, where v_p determines the phase ratio V_s/V_m of the column, and hence the resolution, the specific pore volume of a packing is of minor importance. For silicas it ranges from 0.5 to 1.5 ml g⁻¹.

4.1.4. Specific surface area, a_s

The specific surface area of a packing controls the capacity and retention of solutes in all interaction modes in column liquid chromatography. This holds for both parent and bonded packings. As packings differ in their packing density, ρ_p , from 0.2 to 0.8 g ml⁻¹, the specific surface area in m² g⁻¹ must be multiplied by the

TABLE I

PHYSICAL STRUCTURE PARAMETERS OF SUPPORTS AND PACKINGS¹⁴

Term	Symbol	Definition
Particle shape		Angular, spherical
Particle size	d_p	Particle diameter defined according to the method of determination (see Table 4)
Average particle size	d_{p50}	Average particle diameter at 50% of the cumulative distribution (median), d_{p50} or the most frequent average particle diameter of the relative distribution (mode), d_{pm}
	d_{pm}	
Particle size distribution	d_{psd}	Number, volume, weight or surface area distribution
Specific pore volume	v_p	Uptake in ml of liquid per unit mass or unit volume of packing to fill the internal pores
Micropore volume	$v_p(\text{micro})$	v_p of pores of $p_d < 2 \text{ nm}$
Mesopore volume	$v_p(\text{meso})$	v_p of pores of $2 < p_d < 50 \text{ nm}$
Macropore volume	$v_p(\text{macro})$	v_p of pores of $p_d > 50 \text{ nm}$
Specific surface area	a_s	Internal and external surface area per unit mass or volume of packing
Pore shape		Assumed to be cylindrical in most instances
Pore diameter	p_d	Width of the pore of a given shape
Micropores		$p_d < 2 \text{ nm}$
Mesopores		$2 < p_d < 50 \text{ nm}$
Macropores		$p_d > 50 \text{ nm}$
Hydraulic pore diameter	p_{dn}	Ratio of 4 times the specific pore volume divided by the specific surface area
Kelvin pore diameter	p_{dk}	Pore diameter according to the Kelvin equation
Washburn pore diameter	p_{dw}	Pore diameter according to the Washburn equation
Interstitial column porosity	ε_0	Ratio of intraparticle column volume to total geometric column volume
Internal column porosity	ε_p	Ratio of interparticle column volume to total geometric column volume
Total column porosity	$\varepsilon(\text{total})$	$\varepsilon(\text{total}) = \varepsilon_0 + \varepsilon_p$
Average pore diameter	p_{d50}	Average pore diameter at 50% of the cumulative distribution (median), p_{d50} or the most frequent average pore diameter of the relative distribution (mode), p_{dm}
Pore diameter distribution	p_{dd}	Distribution of v_p or a_s as a function of the average pore diameter

packing density in order to obtain the effective surface area per millilitre of column volume¹⁶. a_s values of 10–200 m² ml⁻¹ are sufficient for improving retention. Larger surface areas, generated by pores < 4 nm in diameter, have a number of disadvantages such as slow kinetics, slow regeneration and easy fouling.

4.1.5. Pore diameter, p_d

A pore diameter of about 10 nm accounts for the majority of separations of solutes of $M < 2$ kdaltons. For larger molecules, pore diameters of ca. 30 nm and more are preferable in order to overcome the low diffusivities. Another advantage of large-pore packings is attributed to the improved surface homogeneity compared with small-pore packings. They also permit more rapid and complete regeneration. The pore size distribution usually spans one decade of pore diameter. As above, small pores of $p_d < 4 \text{ nm}$ should be absent.

Adjustment of the desired physical structure parameters of a packing through the manufacturing process creates fewer problems than the appropriate design of the surface chemistry in terms of retention, selectivity, stability, etc.

4.2. Chemical structure parameters¹⁴

Grouped according to their bulk composition, packings include inorganic materials and a variety of organic gels (see Table 2). In the last 5 years there have been successful attempts to manufacture packings with improved properties and higher batch-to-batch reproducibility. In general, the following criteria relate to retention and selectivity, type(s) of surface functional groups and their respective interactions

TABLE 2

SURVEY OF TYPES OF PACKINGS IN PREPARATIVE AND PROCESS CHROMATOGRAPHY ACCORDING TO THEIR BULK COMPOSITION

1 Inorganic materials

Oxides	(silica, alumina, magnesia)
Carbonates	(magnesium carbonate)
Silicates	(magnesium silicate, aluminosilicates)
Carbon	
Phosphates	(zirconium phosphate, calcium phosphate)

2 Organic gels

Cellulose
Agarose
Dextran
Polyacrylamide
Polyamide
Poly(hydroxyethyl methacrylate)
Styrene–divinylbenzene copolymers
Poly(ethylene glycol dimethacrylate)
Poly(vinyl alcohol)
Poly(vinyl acetate)

3 Chemically bonded silicas

Reversed-phase silicas

$\equiv \text{SiR}$	R = methyl ethyl <i>n</i> -butyl <i>n</i> -hexyl <i>n</i> -octyl <i>n</i> -octadecyl phenyl
---------------------	---

Polar bonded silicas

$\equiv \text{Si(R')R'}$	R' = diol amino nitro cyano biospecific ligands (low to high molecular weight)
--------------------------	--

4 Composites

Silica/polymer gels

with solutes; density of functional groups at the surface; distribution of functional groups across the particle; accessibility of surface functional groups to solutes; and type of matrix.

An inspection of the surface functionality of packings indicates a broad variety of groups from polar to non-polar, acidic and basic with graduated pK values, and with various polar functionality. A common feature is that packings often bear more than a single type of surface functional group, as is the case for chemically bonded phases. Depending on the type of parent matrix, either hydrophobic or hydrophilic interactions are observed to contribute to solute retention. The ligand density of bonded groups ranges from maximum, which is rarely achieved, to low densities. Functional groups bonded as a monolayer exhibit distinct changes in their structure, depending on solvation, with respect to chain length. As an alternative to the monolayer type, bonding is performed in such a way that a multilayer is formed, with internal cross-linking. Specific functional groups are bonded at the outer layer in a diluted state, or spaced by extended hydrophilic or hydrophobic groups, in order to control solute accessibility. All the above cases reflect the current design of packings for bonded phase adsorption, ion-exchange and affinity chromatography.

5 SURVEY OF COMMERCIAL PACKINGS IN PREPARATIVE AND PROCESS-SCALE CHROMATOGRAPHY

This survey deals exclusively with packings with an average particle diameter $d_p > 20 \mu\text{m}$, as otherwise all analytical packings would also have to be listed. For information on analytical packings, see refs. 17 and 18.

5.1 Adsorbents (see Table 3)

Among inorganic adsorbents, silica-based materials, available in graduated particle sizes and size distributions, are the most widely used^{19,20}. Most of the products are of technical grades and were not specifically designed for high-quality preparative separations. The specific surface areas range from 300 to 500 $\text{m}^2 \text{ g}^{-1}$. At packing densities of about 0.5 g ml^{-1} , a_s values of 150–250 m^2 per ml column volume are achieved. Some commercial products are of the macroporous type, with surface areas lower than 50 $\text{m}^2 \text{ g}^{-1}$. In order to improve the limited stability at high pH, attempts were made to dope silica with zirconia and alumina. However, all these manipulations remain fairly inefficient as long as the bulk structure is amorphous. In this context, it is worth mentioning that purely crystalline silica, e.g., silicalite I, or a crystalline silica-rich pentasil type of zeolite with an $\text{SiO}_2/\text{Al}_2\text{O}_3$ ratio above 100, are insoluble in strongly alkaline media²¹. Unfortunately they contain such small micropores that they cannot be applied in liquid chromatography.

Bonded phases include *n*-octyl- and *n*-octadecyl-modified silicas for reversed-phase chromatography and a small number of the polar bonded silica types.

There has been little progress in terms of purity, defined phase composition and pore size in the manufacture of aluminas and other materials for chromatography. The traditional aluminas, adjusted to a certain acidity and basicity, are still on the market²⁰.

The same situation is met with organic-based adsorbents. The classical ones,

TABLE 3
SURVEY OF COMMERCIAL ADSORBENTS IN COLUMN LIQUID CHROMATOGRAPHY ($d_p > 20 \mu\text{m}$)

Abbreviations used: * = angular, o = spherical, b = bulk material, c = column.

Type	Name	Supplier	Form	$d_p (\mu\text{m})$	$a_s (\text{m}^2\text{g}^{-1})$	$p_d (\text{nm})$	Comments
Silica	Matrix Silica Media	Amicon, Grace	* ^a ,b	20, 30, 50, 105	540	6	pH of a 5% (w/w) suspension 6.0–6.5
Silica	XWP 500 Å XWP 1000 Å XWP 1500 Å	Amicon, Grace Amicon, Grace Amicon, Grace	* ^a ,b *,b *,b	30–100 30–100 30–100	60 40 28	50 100 150	
Silica	Bakerbond normal-phase silica gel	Baker	* ^a ,b	32–62, 50–200	500	6	
Silica	Bio-Sil HA Bio-Sil A	Bio-Rad Bio-Rad	* ^a ,b *,b	<100 20–44, 80–150	— —	— —	
Silica	ICN silica	ICN	* ^a ,b	0–63, 32–100, 63–100, 63–200, 100–200, 200–500	550	6	
Silica	ICN silica N	ICN	* ^a ,b	18–32, 32–63	550	6	
Silica	KC-Mikropel M	Kali Chemie	o,b	30–60	210 130 76 65 55	10 18 27 34 43	
Silica	KC-Mikropel L Nucleosil 100–30 Polygosil 60	Kali Chemie Macherey-Nagel Macherey-Nagel	o,b o,b *,b	100–200 30±10 15–25, 25–40, 40–63, 63–100	350 500	10 6	
	Polygosil 100	Macherey-Nagel	*,b	25–40, 40–63	300	10	

(Continued on p. 238)

TABLE 3 (continued)

Type	Name	Supplier	Form	d_p (μm)	a_s (m^2g^{-1})	p_d (nm)	Comments
Silica	Kieselgel 40	Merck	* ^a ,b	63–200 200–500	>500	4	pH of a 10% (w/w) suspension \approx 7, content of Fe 0.02%, Cl 0.03%
	Kieselgel 60	Merck	* ^a ,b	<63 63–200 200–500	500 500 500	6 6 6	
	Kieselgel 100	Merck	* ^a ,b	63–200 200–500	250 250	10 10	
	Kieselgel 60	Merck	* ^a ,b	15–40 40–63 63–100	500	6	Narrow size classification
	Kieselgel 60 renst	Merck	* ^a ,b	63–200	500	6	Highly pure grade, Fe 0.002%, Cl 0.008%
Silica	LiChroprep Si 40	Merck	* ^a ,b	15–25 40–63	—	—	
	LiChroprep Si 60	Merck	* ^a ,b,c	15–25 40–63	—	—	
	LiChroprep Si 100	Merck	* ^a ,b	15–25 40–63	—	—	
Silica	Kieselguhr	Merck	* ^a ,b	—	—	—	
	Porasil A	Millipore, Waters	0,b	37–75 75–125	300–500		
	Porasil B	Millipore, Waters	0,b	37–75 75–125	140–230		
Silica	Prep-PAK 500 silica	Millipore, Waters	—	55–105	—	—	
Silica	Vydac TP silica Vydac HS silica	Separations Group	* ^a ,b,c 0,b,c	20–30 20–30	80 500	30 8	
Silica	LPS-1 LPS-2	Whatman Whatman	* ^a ,b * ^a ,b	13–24 37–53	250 450		

Reversed-phase silica	Matrix silica Media C ₈ C ₁₈	Amicon, Grace	* ^a ,b	20, 30 50, 105	-	6 10 25	<i>n</i> -Octyl and <i>n</i> -octadecyl groups bonded
Reversed-phase silica	Bakerbond Methyl Ethyl Butyl, Hexyl <i>Octyl</i> , Octadecyl Phenethyl Diphenyl	Baker	* ^a ,b	40	~500	~6	<i>n</i> -Octyl groups bonded <i>n</i> -Octadecyl groups bonded
Reversed-phase silica	ICN silica RP-8 ICN silica RP-18	ICN ICN	* ^a ,b *,b	18–32, 32–63 18–32, 32–63	-	-	<i>n</i> -Octyl groups bonded <i>n</i> -Octadecyl groups bonded
Reversed-phase silica	Nucleosil 30 C ₁₈ Polygosil 60 C ₈ Polygosil 60 C ₁₈	Macherey–Nagel Macherey–Nagel Macherey–Nagel	o,b *,b *,b	30±10 25–40, 40–63 25–40, 40–63	-	-	<i>n</i> -Octadecyl groups bonded <i>n</i> -Octyl groups bonded <i>n</i> -Octadecyl groups bonded
Reversed-phase silica	Prep-PAK Vydac C4	Millipore, Waters	c c	30 30	-	-	<i>n</i> -Butyl groups bonded
Reversed-phase silica	Prep-PAK Vydac C ₁₈ 500 C ₁₈	Millipore, Waters	c c	55–105	-	-	<i>n</i> -Octadecyl groups bonded
Reversed-phase silica	Bondapak C ₁₈ / Porasil B	Millipore, Waters	o,b	37–75	-	-	<i>n</i> -Octadecyl groups bonded
Silica, silanized	Kieselgel 60 silanized	Merck	* ^a ,b	63–200	-	6	Dimethylsilyl functional groups
Reversed-phase silica	Kieselgel 60 silanized	Merck	* ^a ,b *,b,c	63–200 25–40 5–20, 15–25, 25–40, 40–63	500 - -	6 - -	Dimethylsilyl groups bonded <i>n</i> -Octyl groups bonded
	LiChroprep RP-2 LiChroprep RP-8	Merck Merck					(Continued on p. 240)

TABLE 3 (continued)

Type	Name	Supplier	Form	d_p (μm)	a_s (m^2g^{-1})	p_4 (nm)	Comments
Reversed-phase silica	LiChroprep RP-18	Merck	* , b, c	5-20, 15-25, 25-40, 40-63	-	-	<i>n</i> -Octadecyl groups bonded
Reversed-phase silica	Vydac 201 HS		o, b, c	20-30	-	-	<i>n</i> -Octadecyl groups bonded
	Vydac 201 TP		* b, c	20-30	-	-	<i>n</i> -Octadecyl groups bonded
	Vydac 214 TP		* b, c	20-30	-	-	<i>n</i> -Butyl groups bonded
	Vydac 218 TP		* , b, c	20-30	-	-	<i>n</i> -Octyl groups bonded
	Vydac 219 TP	Synchroprep	* , b, c	20-30	-	-	Diphenyl groups bonded
Reversed-phase silica	Synchroprep RP-P C ₁₈	Synchroprep	b, c	30	-	-	<i>n</i> -Octadecyl groups bonded
	Synchroprep RP-P C ₈	Synchroprep	b, c	30	-	-	<i>n</i> -Octyl groups bonded
	Synchroprep RP-P C ₄	Synchroprep	b, c	30	-	-	<i>n</i> -Butyl groups bonded
Reversed-phase silica	Synchroprep RP-P C ₁	Synchroprep	* , b	13-24	-	-	Methyl groups bonded
	LRP-1	Whatman	* , b	37-53	-	-	<i>n</i> -Octadecyl groups bonded
	LRP-2	Whatman	* , b	37-53	-	-	<i>n</i> -Octadecyl groups bonded
Polar bonded silicas	Bakerbond normal-phase Diol	Baker	* , b	40	500	6	Diol groups bonded Cyano groups bonded
Chiral phases	DNBPG-ionic	Baker	* , b	40	-	-	(R)-N-3,5-Dinitrobenzoylphenylglycine
Polar bonded silicas	DNB Leu-kovalent LiChroprep Diol	Baker Merck	* b * , b, c	40 25-40, 40-63	-	-	Diol groups bonded
	LiChroprep NH ₂	Merck	* b	25-40, 40-63	-	-	Amino groups bonded
	LiChroprep CN	Merck	* , b, c	40-63	-	-	Cyano groups bonded
Alumina	Neutral alumina AG 7	Bio-Rad	* , b	-	-	-	pH 6.9-7.1
	Basic alumina AG 10	Bio-Rad	* , b	-	-	-	pH 10.0-10.5
	Acid alumina AG 4	Bio-Rad	* , b	-	-	-	pH 3.5-4.5

Alumina	ICN alumina N	ICN	* ^a ,b	18–32, 32–63	200	6	pH 7.5
	ICN alumina A	ICN	* ^a ,b	18–32	200	6	pH 4.5
	ICN alumina B	ICN	* ^a ,b	18–32	200	6	pH 10
	Aluminumoxid 60, aktiv basisch	Merck	* ^a ,b	63–200	—	6	pH 9.0 ± 0.5
Alumina	Aluminumoxid 90, aktiv basisch	Merck	* ^a ,b	63–200	—	9	pH 9.0 ± 0.5
	Aluminumoxid 90, aktiv neutral	Merck	* ^a ,b	63–200	—	9	pH 7.3 ± 0.5
	Aluminumoxid 90, aktiv sauer	Merck	* ^a ,b	63–200	—	9	pH 4.0 ± 0.5
	Aluminumoxid 150, basisch	Merck	* ^a ,b	63–200	—	15	pH 9.0 ± 0.5
	LiChroprep Alox T	Merck	* ^a ,b	25–40	—	—	Basic alumina
					Bulk composition MgO SiO ₂ = 15 : 85		
Magnesium silicate	Florsil	Merck	* ^a ,b	75–150, 150–200	—	—	
Cellulose	Matrex	Amicon, Grace	* ^a ,b	—	—	—	
	Cellufine					—	
Cellulose	Cellulose	Amicon, Grace	o,b			—	
	Matrex	Amicon, Grace	o,b			—	
	Cellufine					—	
Dextran	AM	Amicon, Grace	b			—	
	Matrex	Amicon, Grace	b			—	
	Cellufine					—	
	Dextran	Amicon, Grace	b			—	
Agarose	Matrex	Amicon, Grace	b	—		—	
	Cellufine					—	
	Agarose					—	
Macroporous styrene– divinyl- benzene	Bio-Beads SM-2	Bio-Rad	o,b		300	9	
copolymers	Bio-Beads SM-4	Bio-Rad	o,b	—	725	4	
Acrylic ester	Bio-Beads SM-7	Bio-Rad	o,b	—	450	9	
Cellulose, acetylated	Cellulose CEL AC-30X	Macherey-Nagel	* ^a ,b	15–85			
	Cellulose CEL AC-40X	Macherey-Nagel	* ^a ,b	15–35			

TABLE 3 (*continued*)

Type	Name	Supplier	Form	d_p (μm)	a_s ($m^2 g^{-1}$)	p_d (nm)	Comments
Polyamide	PA-6/2032	Macherey-Nagel	* ^a ,b	20-32	—	—	—
Cellulose	Cellulose	Merck	* ^a ,b	20-100	—	—	—
	Makrokristallin						
Avicel							
Styrene-	Ambertite XAD-2	Merck	0,b	20-50			
divinyl-	Ambertite XAD-4	Merck	0,b	20-50			
benzene							
copolymers							
acrylic	Ambertite XAD-7	Merck	0,b	20-50			
ester	Ambertite XAD-8	Merck	0,b	20-50			
Crosslinked	Phenyl-	Pharmacia	0,b				
agarose	Sephadose						
	Octyl-	Pharmacia	0,b				
	Sephadose						

such as cellulose, dextran, agarose and styrene–divinylbenzene copolymers, still dominate, while the pressure-stable, highly cross-linked polymers with large pore sizes have not yet been introduced as preparative packings.

5.2. *Size exclusion packings (see Table 4)*

A wide variety of organic-based gels of graduated exclusion limits are on the market, based on classical styrene–divinylbenzene copolymers, polyacrylamide and methacrylate copolymers with different rigidities. Porous silicas and porous glasses are available as inorganic SEC packings. They carry appropriate functional groups, depending on the application, for the SEC of synthetic materials or biopolymers.

5.3. *Ion-exchange packings (see Table 5)*

Basic organic and inorganic packings serve as starting materials for ion exchangers, available as strong to weak cation and anion exchangers. The materials differ in their effective ion-exchange capacities and, relatedly, in the degree of cross-linking and pore size.

Major emphasis is placed on ion exchangers for use in protein separations, *i.e.*, mostly anion exchangers. For this purpose, calcium phosphate or hydroxyapatite are also employed.

5.4. *Affinity packings (see Table 6)*

The largest number of packings, with an enormous diversity with regard to biospecific affinity, is found in affinity chromatography. Packings are categorized into activated packings and those ready-for-use, carrying group-specific ligands and more biospecific ligands. Activated affinity packings offer the choice of preparing the desired material for a given separation problem through a coupling reaction. Typical activator groups are N-hydroxysuccinimide ester, carboxyl and carboxymethyl groups, amino and oxirane groups, imidocarbonate and 2-pyridyldisulphide groups.

6 KEY ASPECTS IN CHOOSING A PHASE SYSTEM FOR PREPARATIVE AND PROCESS CHROMATOGRAPHY

Chromatographic separation techniques are commonly applied as a last step in purification processes. As is apparent from the preceding discussion, a high chromatographic resolution is necessary in order to achieve the desired purity and yield at an economically acceptable cost, and hence this feature governs the choice of a suitable LC mode. The type(s) of phase system to be selected is primarily determined by the chemical structure properties of the desired product relative to those of the contaminants and by-products. Obviously, the LC modes differ in their selectivity, such as size and shape (size exclusion chromatography), charge (ion-exchange chromatography), polarity and type of functional groups (adsorption chromatography), isoelectric point (chromatofocusing), hydrophobic character (reversed-phase and hydrophobic interaction chromatography), biological affinity (affinity chromatography)²². It is often the case that a single-step procedure based on one LC mode

TABLE 4
SURVEY OF COMMERCIAL SIZE EXCLUSION PACKINGS ($d_p > 20 \mu\text{m}$)
For abbreviations, see Table 3

Type	Name	Supplier	Form	$d_p (\mu\text{m})$	p_d (nm)	$a_s (m^2 g^{-1})$	Molecular weight fractionation range (daltons)
Silica	Fractosil 200	Merck	* ^a ,b	40–63/63–125	18	150	< 50 000 (polystyrenes)
	Fractosil 500	Merck	* ^a ,b	40–63/63–125	50	50	< 400 000 (polystyrenes)
	Fractosil 1000	Merck	* ^a ,b	40–63/63–125	100	20	< 1 000 000 (polystyrenes)
	Fractosil 2500	Merck	* ^a ,b	63–125	250	8	
	Fractosil 5000	Merck	* ^a ,b	63–125	500	3	
	Fractosil 10 000	Merck	* ^a ,b	63–125	1000	1.5	
	Fractosil 25 000	Merck	* ^a ,b	63–125	2500	0.6	
	SynChroprep	SynChrom	* ^a ,b	60–120			
	GPC 25 000	SynChroprep	SynChrom	* ^a ,b	60–120		
	GPC 10 000	SynChroprep	SynChrom	* ^a ,b	60–120		
Silica with a carbohydrate layer	SynChroprep	SynChrom	* ^a ,b	60–120			
	GPC 5000	SynChroprep	SynChrom	* ^a ,b	60–120		
	SynChroprep	SynChrom	* ^a ,b	60–120			
	GPC 2500	SynChroprep	SynChrom	* ^a ,b	60–120		
	Silica with polymerized polyamine coating	CATSEC 25 000	SynChroprep	SynChrom	* ^a ,b	60–120	
	Polyamine	SynChroprep	SynChrom	* ^a ,b	60–120		
	CATSEC 10 000	SynChroprep	SynChrom	* ^a ,b	60–120		
	CATSEC 5000	SynChroprep	SynChrom	* ^a ,b	60–120		
	SynChroprep	SynChrom	* ^a ,b	60–120			
	CATSEC 2500	Pierce	* ^a ,b	37–74	10	170	1000–30 000 (dextrans)
Porous glass	CPG-100	Pierce	* ^a ,b	37–74	24	130	2500–125 000 (dextrans)
	CPG-240	Pierce	* ^a ,b	37–74	50	70	11 000–350 000 (dextrans)
	CPG-500	Pierce	* ^a ,b	37–74/125–177			1000–8000 (dextrans)
	CPG-40	Pierce	b	37–74	4		
Porous glass with bonded glykophase	Glykophase						
	CPG-100	Pierce	b	37–74	10		1000–30 000 (dextrans)
glycerol phase	Glykophase						

CPG-200	Pierce	b	37-74	20
Glykophase	Pierce	b	37-74	46
CPG-460	Pierce	b	37-74	11 000-350 000 (dextrans)
Glykophase				10 000-60 000 (globular proteins)
Cellulose	Matrex	Amicon, Grace	o,b	< 10
Celluline GC 100	Matrex	Amicon, Grace	o,b	< 20
Celluline GC 200	Matrex	Amicon, Grace	o,b	< 20
Celluline GC 700	Matrex	Amicon, Grace	o,b	< 70
GCL 2000	Celluline Celfulfine	Amicon, Grace	o,b	< 300
Bio-Gel A-0.5 m	Bio-Rad	o,b	40-80/80-150	10 000-20 000 000 (globular proteins)
Bio-Gel A-1.5 m	Bio-Rad	o,b	40-80/80-150	10 000-500 000 (globular biomolecules)
Bio-Gel A-5 m	Bio-Rad	o,b	40-80/80-150	10 000-150 000 000 (globular biomolecules)
Bio-Gel A-15 m	Bio-Rad	o,b	40-80/80-150	10 000-50 000 000 (globular biomolecules)
Bio-Gel A-50 m	Bio-Rad	o,b	80-150/150-300	100 000-500 000 000 (globular biomolecules)
Bio-Gel A-150 m	Bio-Rad	o,b	80-150/150-300	1 000 000-150 000 000 (globular biomolecules)
Sephadose 2B	Pharmacia	o,b	60-200	$7 \cdot 10^4$ - $4 \cdot 10^7$ (proteins)/ 10^5 - 2×10^7 (polysaccharides)
Sephadose 4B	Pharmacia	o,b	60-140	$6 \cdot 10^4$ - $2 \cdot 10^7$ (proteins) $3 \cdot 10^{10}$ - $5 \cdot 10^6$ (polysaccharides)
Sephadose 6B	Pharmacia	o,b	45-165	10^4 - $4 \cdot 10^6$ (proteins)/ 10^4 - 10^6 (polysaccharides)
Sephadose CL-2B	Pharmacia	o,b	60-200	See Sepharose
Sephadose CL-4B	Pharmacia	o,b	60-140	See Sepharose
Sephadose CL-6B	Pharmacia	o,b	45-165	See Sepharose
Sephadex G-10	Pharmacia	o,b	40-120	< 700 (globular proteins)/< 700 (dextrans)
Sephadex G-15	Pharmacia	o,b	40-120	< 1500 (globular proteins)/< 1500 (dextrans)
Sephadex G-25	Pharmacia	o,b	10-40/20-80	1000-5000 (globular proteins)/100-5000 (dextrans)
Sephadex G-50	Pharmacia	o,b	50-150/100-300	1500-30 000 (globular proteins)/500-10 000 (dextrans)
Sephadex G-75	Pharmacia	o,b	50-150/100-300	3000-80 000 (globular proteins)/1000-50 000 (dextrans)
Sephadex G-100	Pharmacia	o,b	10-40/40-120	4000-150 000 (globular proteins)/1000-50 000 (dextrans)
Sephadex G-150	Pharmacia	o,b	10-40/40-120	5000-300 000 (globular proteins)/1000-150 000 (dextrans)
Sephadex G-200	Pharmacia	o,b	10-40/40-120	5000-600 000 (globular proteins)/1000-200 000 (dextrans)

(Continued on p. 246)

Type	Name	Supplier	Form	d_p (μm)	p_d (nm)	a_s ($m^2\text{g}^{-1}$)	Molecular weight fractionation range (daltons)
Cross-linked dextran superfine	Sephacryl S-200 Pharmacia	o,b	40–105		5 · 10 ³ –2 · 10 ⁵ (proteins)/1 (polysaccharides)	10 ³ –8 · 10 ⁴	
Cross-linked dextran superfine	Sephacryl S-300 Pharmacia	o,b	40–105		1 · 10 ⁴ –1 · 5 · 10 ⁶ (proteins)/2 (polysaccharides)	10 ³ –4 · 10 ⁵	
Cross-linked dextran superfine	Sephacryl S-400 Pharmacia	o,b	40–105		2 · 10 ⁴ –8 · 10 ⁶ (proteins)/1 10 ⁴ –2 · 10 ⁶ (polysaccharides)	10 ³ –4	
Cross-linked dextran superfine	Sephacryl S-500 Pharmacia	o,b	40–105		4 · 10 ⁴ –2 · 10 ⁷ (polysaccharides)	10 ⁴ –2 · 10 ⁷	
Polyethylene glycol 2000	Fractogel PGM Merck	* ^a ,b	40–105		5 · 10 ⁵ –10 ⁸ (polysaccharides)	< 2000 (polyethylene glycol)	
Polyacrylic acid dimethyl amide	Bio-Gel P-2	Bio-Rad	o,b	< 40, 40–80		100–1800 (globular biomolecules)	
Polyacrylic acid dimethyl amide	Bio-Gel P-4	Bio-Rad	o,b	< 40, 40–80, 80–150		800–4000 (globular biomolecules)	
Polyacrylic acid dimethyl amide	Bio-Gel P-6	Bio-Rad	o,b	< 40, 40–80, 80–150, 150–300		1000–6000 (globular biomolecules)	
Polyacrylic acid dimethyl amide	Bio-Gel P-10	Bio-Rad	o,b	< 40, 40–80, 80–150, 150–300		1500–20000 (globular biomolecules)	
Hydrophilic polymer G 6000 PW	Toyo Soda	o,c	25 ± 5		2500–40000 (globular biomolecules)		
Hydrophilic cross-linked HW-40 vinyl polymer	Fractogel TSK Merck	* ^a ,b	25–40, 32–63, 50–100		3000–60000 (globular biomolecules)	100–200000 (dextran)	
Hydrophilic cross-linked HW-40	Fractogel HW-50 Merck	* ^a ,b	25–40, 32–63		5000–100000 (globular biomolecules)	100–100000 (globular proteins)	
Hydrophilic cross-linked HW-40	Fractogel HW-55 Merck	* ^a ,b	25–40, 32–63		15000–150000 (globular biomolecules)	50000–500000 (globular proteins)	
Hydrophilic cross-linked HW-40	Fractogel HW-65 Merck	* ^a ,b	25–40, 32–63		30000–200000 (globular biomolecules)	60000–400000 (globular biomolecules)	
Hydrophilic cross-linked HW-40	Fractogel HW-75 Merck	* ^a ,b	25–40, 32–63		1000–6000 (globular biomolecules)	100–10000 (globular proteins)	

Hydrophilic	Toyo Pearl cross-linked vinyl polymer	Toyo Pearl HW-40	Toyo Soda	Product identical with Fractogel TSK HW-40
		Toyo Pearl HW-50	Toyo Soda	Product identical with Fractogel TSK HW-50
	Toyo Pearl HW-55	Toyo Soda	Toyo Soda	Product identical with Fractogel TSK HW-55
	Toyo Pearl HW-65	Toyo Soda	Product identical with Fractogel TSK HW-65	Product identical with Fractogel TSK HW-65
	Toyo Pearl HW-75	Toyo Soda	Product identical with Fractogel TSK HW-75	Product identical with Fractogel TSK HW-75
Styrene- divinyl- benzene copolymer	Styragel 60 Å	Millipore, Waters * ,b,c	<37, 37-75	10-500 (polystyrenes)
	Styragel 100 Å	Millipore, Waters * ,b,c	37-75	50-1500 (polystyrenes)
	Styragel 200 Å	Millipore, Waters * ,c	37-75	50-4000 (polystyrenes)
	Styragel 500 Å	Millipore, Waters * ,b,c	37-75	100-10,000 (polystyrenes)
	Styragel 10 ³ Å	Millipore, Waters * ,c	37-75	200-30,000 (polystyrenes)
	Styragel 10 ⁴ Å	Millipore, Waters * ,c	37-75	5000-6 · 10 ⁵ (polystyrenes)
	Styragel 10 ⁵ Å	Millipore, Waters * ,c	37-75	50,000-4 · 10 ⁶ (polystyrenes)
	Styragel 10 ⁶ Å	Millipore, Waters * ,c	37-75	2 · 10 ⁵ -1 · 10 ⁷ (polystyrenes)
	Styragel 10 ⁷ Å	Millipore, Waters * ,c	37-75	5 · 10 ⁵ -2 · 10 ⁷ (polystyrenes)
Styrene- divinyl- benzene copolymer	HN-X 2.00	Hamilton o,b	<30, 50	
	4.00/6.00/6.25/ 6.50/6.75/7.00/ 7.25/7.50/7.75/			
	8.00/8.25/8.50/ 8.75/9.00/9.50/ 10.00/11.00/12.00/ 15.00/20.00/25.00/ 30.00/35.00			(% cross-linkage)
Styrene- divinyl- benzene copolymer	Bio-Beads S-X1 Bio-Beads S-X2 Bio-Beads S-X3 Bio-Beads S-X4 Bio-Beads S-X8 Bio-Beads S-X12	Bio-Rad Bio-Rad Bio-Rad Bio-Rad Bio-Rad Bio-Rad	b b b b b b	40-80 40-80 40-80 40-80 40-80 40-80

(Continued on p. 248)

TABLE 5

SURVEY OF COMMERCIAL ION EXCHANGERS ($d_p > 20 \mu\text{m}$)

Type	Name	Supplier	Form	$d_p (\mu\text{m})$	Ion-exchange capacity (mequiv ml^{-1})	Comments
Cellulose-based ion exchangers	Matrex Cellufine AM	Amicon, Grace	o,b	—	0.18	DEAE anion exchanger, low to medium molecular weight solutes
	Matrex Cellufine AH	Amicon, Grace	o,b	—	0.14	DEAE anion exchanger medium to high molecular weight solutes
	Matrex Cellufine CM	Amicon, Grace	o,b	—	0.21	Carboxymethyl cation ion exchanger
Cross-linked agarose-based ion exchanger	DEAE-Bio gel A	Bio-Rad	o,b	—	0.02	
	CM-Bio gel A	Bio-Rad	o,b	—	0.02	
	Bio-Rex 70	Bio-Rad	o,b	—	1.5	
Acrylic polymer-based cation exchanger	Styrene-divinylbenzene copolymer-based ion exchanger	Ammax A-4	Bio-Rad	o,b	20 ± 4	Strong cation exchanger
		Ammax Q-150 S	Bio-Rad	o,b	28 ± 7	Strong cation exchanger
		Ammax Q-15 S	Bio-Rad	o,b	22 ± 3	Strong cation exchanger
		Ammax 50 W-X4	Bio-Rad	o,b	25 ± 5	Strong cation exchanger
	Ammax A-14	Bio-Rad	o,b	32.5 ± 1.5	1.7	Strong cation exchanger
	HPX-42 A	Bio-Rad	o,c	20 ± 3	1.2	Ag form
	HPX-42 C	Bio-Rad	o,c	25		Ca form
Sulphonated styrene-divinylbenzene copolymer for carbohydrate analysis	Styrene-divinylbenzene-based ion exchangers	HC-X, 200 up to HC-X 35.00	Hamilton	o,b	20-25	
		HA-X 4 up to HA-X 10	Hamilton	o,b	20-25	—
		DE 52	Pierce	b	—	
Strong anion exchanger $[\text{N}(\text{CH}_3)_3\text{Cl}]$	Cellulose-based weak anion exchanger (DEAE)	CM 52	Pierce	b	1.0	
Cellulose-based weak cation exchanger (carboxymethyl)	Styrene-divinylbenzene copolymer-based cation exchangers	Amblyst	Merck	o,b	20-50	

Lewatit SP 1000	Merck	o,b	60–150
Ambberlite OG-501	Merck	o,b	100–200
Ambberlite IRC 50	Merck	o,b	20–50
Ambberlite IR-120	Merck	o,b	20–50
Lewatit S 1080	Merck	o,b	60–150
Ambberlite IRA-400	Merck	o,b	20–50
Lewatit M 5080	Merck	o,b	20–50
Ambberlyst A-26	Merck	o,b	20–50
Lewatit MP 5080	Merck	o,b	60–150
Ambberlite IR-45	Merck	o,b	20–50
Ambberlyst A-21	Merck	o,b	20–50
Lewatit MP 7080	Merck	o,b	60–150
Fractogel	Merck	*,b	25–50
TSK			49–90
DEAE 650	Merck	*,b	25–50
Fractogel			45–90
TSK			
CM 650	Millipore, Waters	b	37–55
Acell	Millipore, Waters	b	37–55
QAE	Millipore, Waters	b	37–55
Acell	Millipore, Waters	b	37–55
CM	Pharmacia	o,b	40–125 (dry)
DEAE-Sephadex	Pharmacia	o,b	40–125 (dry)
QAE-Sephadex	Pharmacia	o,b	40–125 (dry)
CM-Sephadex	Pharmacia	o,b	40–125 (dry)
SP-Sephadex	Pharmacia	o,b	40–125 (dry)
DEAE-Sepharose	Pharmacia	o,b	45–165 (wet)
CM-Sepharose	Pharmacia	o,b	45–165 (wet)
DEAE-Sephadcel	Pharmacia	o,b	40–160
Bakerbond	Baker	*,b	40
ion exchanger			11
WAX			
Ammonopropyl	Baker	*,b	40
WAX			14
Diammino	Baker	*,b	40
SAX			06
Quaternary			
Amine	Baker	*,b	40
WCX			09
Carboxylated			

(Continued on p. 250)

TABLE 5 (*continued*)

Type	Name	Supplier	Form	d_p (μm)	Ion-exchange capacity (mequiv m^{-2})	Comments
SCX	Baker	* ^a ,b	40	0.8		
aliphatic sulphonic acid						
SCX	Baker	* ^a ,b	40	0.9		
aromatic sulphonic acid						
Silica-based ion exchanger	SynChroprep AX 300	SynChrom	b,c	30	—	
	SynChroprep Q 300	SynChrom	b,c	30	—	
	SynChroprep CM 300	SynChrom	b,c	30		
	SynChroprep S 300	SynChrom	b,c	30		
Porous glass based ion exchanger	CPG/CM Glycophase	Pierce	* ^a ,b	74-125		
	CPG/DEAE Glycophase	Pierce	* ^a ,b	74-125		
	CPG/QAE Glycophase	Pierce	* ^a ,b	74-125		
	CPG/SP Glycophase	Pierce	* ^a ,b	74-125		
Calcium phosphate (hydroxyapatite)	Bio-Gel HT	Bio-Rad	b	—	10 mg g ⁻¹ BSA	
	Bio-Gel HTP	Bio-Rad	b	—	10 mg g ⁻¹ BSA	
Calcium phosphate	Hydroxylapatite	Merck	o,b	75-180		
	spharsisch					
						Bulk composition 38.3% Ca, 19.7% P

TABLE 6
SURVEY OF COMMERCIAL AFFINITY PACKINGS ($d_p > 20 \mu\text{m}$)

Type	Name	Supplier	Form	$dp/\mu\text{m}$	Activator group or ligand	Binding capacity	Ligand specificity
<i>Activated affinity supports</i>							
Cross-linked agarose	Affi-Gel 10	Bio-Rad	o,b	N-Hydroxysuccinimide ester on 10-atom, neutral, hydrophilic spacer	15 $\mu\text{mole ml}^{-1}$	Ligands with primary amino groups	
	Affi-Gel 15	Bio-Rad	o,b	N-Hydroxysuccinimide ester on 15-atom, alkaline spacer	15 $\mu\text{mole ml}^{-1}$	Ligands with primary amino groups	
CM Bio-Gel A		Bio-Rad	o,b	Carboxymethyl group (carbobimide method)	20 $\mu\text{mole ml}^{-1}$	Ligands with terminal amino groups	
Affi-Gel 202		Bio-Rad	o,b	Carboxyl group on 10-atom, hydrophilic spacer (carbobimide method)	20 $\mu\text{mole ml}^{-1}$	Ligands with primary amino groups	
Affi-Gel 102		Bio-Rad	o,b	Amino group on 6-atom, hydrophilic spacer (carbobimide method)	15 $\mu\text{mole ml}^{-1}$	Ligands with carboxyl groups	
Polyacrylamide	Aminoethyl Bio-Gel P-2	Bio-Rad	o,b	40–80 aminoethyl group (carbobimide method)	1 mequiv g^{-1} (dry)	Ligands with carboxyl groups	
Aminoethyl Bio-Gel P-150		Bio-Rad	o,b	80–150 aminoethyl group (carbobimide method)	1 mequiv. g^{-1} (dry)	Ligands with carboxyl groups	
Hydrophilic vinyl polymer	Fractogel TSK AF-Epoxy 650	Merck	* ,b	32–63			
	Fractogel TSK AF-Amino 650	Merck	* ,b				
	Fractogel TSK AF-CDI 650	Merck	* ,b	32–63			
Cellulose	Fractogel TSK AF-NCS 650	Merck	* ,b	32–63			
Aminododecyl-cellulose		Merck	* ,b		Amino group on C-12 spacer (carbobimide method)	0.1 mequiv. ml^{-1}	-COOH
Aminododecyl-cellulose succonylert		Merck	* ,b		Succinimide on C-12 spacer	0.1 mequiv. ml^{-1}	$-\text{NH}_2$

(Continued on p 252)

TABLE 6 (*continued*)

Type	Name	Supplier	Form	<i>dp/μm</i>	Activator group or ligand	Binding capacity	Ligand specificity
Acrylic polymer Agarose	Carboxymethyl-cellulosehydrazid Eupergit C	Merck	* ^a ,b		Carboxymethyl hydrazide	0.1 mequiv ml ⁻¹	-NH ₂
CNBr-activated Sepharose 4B	Rohm Pharma	o,b	30, 150, 250	Oxirane group			
AH-Sepharose 4B	Pharmacia o,b	60-140		Imidocarbonate groups			-NH ₂
CH-Sepharose 4B	Pharmacia o,b	60-140		Amino group on C-6 spacer Carboxyl group on C-5 spacer (carbodiimide required)	6-10 μmole ml ⁻¹ 10-14 μmole ml ⁻¹	-COOH -NH ₂	
Activated CH-Sepharose 4B	Pharmacia o,b	60-140		N-Hydroxysuccinimide ester on C-5 spacer	5-7 μmole ml ⁻¹	-NH ₂	
Epoxy-activated Sepharose 6B	Pharmacia o,b	45-165		Oxirane group on hydrophilic spacer	15-20 μmole ml ⁻¹	-NH ₂ , -OH, -SH	
Activated thiol-Sepharose 4B	Pharmacia o,b	60-140		2-Pyridyl disulphide on glutathione spacer	1 μmole ml ⁻¹		
Thiopropyl-Sepharose 6B	Pharmacia o,b	45-165		2-Pyridyl disulphide on hydroxypropyl spacer	20 μmole ml ⁻¹		
Cross-linked agarose	Pierce	* ^a ,b	45-165 hydrated		Imidazolylcarbamate	>50 μmole ml ⁻¹	-NH ₂
Cross-linked dextran	Reacti-Gel (25DF)	Pierce	* ^a ,b dry		Imidazolylcarbamate	>100 μmole ml ⁻¹	-NH ₂
Polystyrene	Hydrazide beads	Pierce	0,b nonporous		Hydrazide (glutaraldehyde method)	3 μmole per bead	-NH ₂
Alkylamine beads	Pierce	0,b nonporous	0.25 in		Hexylamine (succinic anhydride method)	3 μmole per bead	-NH ₂

Sanger reagent beads	Pierce	o,b nonporous b	0.25 in.	1-Fluoro-2,4-dinitrobenzene on hexylamine spacer	3 μ mole per bead	-NH ₂
React-Gel (GF-2000)	Pierce	Pierce	* _b	Imidazoly carbamate	> 50 μ mole ml ⁻¹	-NH ₂
React-Gel (HW-65 F)	Pierce	Pierce	* _b	Imidazoly carbamate	> 50 μ mole ml ⁻¹	-NH ₂
CPG/CDI-activated Glycophase	Pierce	* _b	74-125	Imidazoly carbamate	> 50 μ mole ml ⁻¹	-NH ₂
CPG/aminoacryl	Pierce	* _b	125-177	Aromatic amino group	-COOH	
CPG/aminopropyl	Pierce	* _b	125-177	Aminopropyl	-COOH	
CPG/carboxyl	Pierce	* _b	125-177	Carboxyl group on 10 Å alkyl spacer	-NH ₂	
CPG/long chain alkylamine	Pierce	* _b	125-177	Amino groups on long alkyl spacer	-COOH	
CPG/NHS glycol phase	Pierce	* _b	125-177	N-Hydroxysuccinimide	-NH ₂	
CPG/stable diazonium salt	Pierce	* _b	125-177	Diazonium borofluoride on aromatic amine spacer	Phenols, aromatic amines	
CPG/thiol	Pierce	* _b	125-177	SH on 10 Å alkyl spacer	-SH, -Hg	
Act-Ultrogel AcA 22	IBF/LKB	* _b	60-140	Glutaraldehyde (Michael addition to the trimer)	-NH ₂	
Polycrylic-amide-agarose gel	Act-Magnogel AcA 44	IBF/LKB	* _b	60-140	Glutaraldehyde (Michael addition to the trimer)	-NH ₂
Polycrylic-amide-agarose gel with 7% Fe ₃ O ₄	AC-Ultrogel AcA 34 HMD-Magnogel AcA 44	IBF/LKB	* _b	60-140	Carboxyl group on C-5 spacer Amino group on C-6 spacer	-NH ₂ -COOH

(Continued on p. 254)

TABLE 6 (continued)

Type	Name	Supplier	Form	$d\eta/\mu m$	Activator group or ligand	Binding capacity	Ligand specificity
<i>Affinity media with bonded ligands</i>							
Silica hydrophilic polymer	Bakerbond MAB Fractogel TSK AF-blue	Baker Merck	* ^a ,b,c *,b	40 32–63	Triazine dyes (coupled to activated Fractogel TSK for BSA HW-65)	11.6 mg ml ⁻¹	Mouse monoclonal IgG Proteins
	Fractogel TSK AF-red	Merck	* ^a ,b	32–63	Triazine dyes (coupled to activated Fractogel TSK for BSA HW-65)	11.6 mg ml ⁻¹	Proteins
	Fractogel TSK AF-green	Merck	* ^a ,b	32–63	Triazine dyes (coupled to activated Fractogel TSK for BSA HW-65)	11.6 mg ml ⁻¹	Proteins
	Fractogel TSK AF-brown	Merck	* ^a ,b	32–63	Triazine dyes (coupled to activated Fractogel TSK for BSA HW-65)	11.6 mg ml ⁻¹	Proteins
	Fractogel TSK AF-orange	Merck	* ^a ,b	32–63	Triazine dyes (coupled to activated Fractogel TSK for BSA HW-65)	11.6 mg ml ⁻¹	Proteins
Cellulose	4-Aminobenzamidine coupled to succinylated aminododecyl-cellulose	Merck	* ^a ,b		4-Aminobenzamidine	Ligand density 90–110 $\mu mol ml^{-1}$	Proteins
	3-Aminobenzene boronic acid coupled to succinylated aminododecylcellulose	Merck	* ^a ,b		3-Aminobenzenboronic acid	Ligand density 90–110 $\mu mol ml^{-1}$	cis-Diols
	Trypsin inhibitor coupled to succinylated aminododecyl-cellulose	Merck	* ^a ,b		Trypsin inhibitor	Ligand density 15–20 $\mu mol ml^{-1}$	Trypsin
	Trypsin (bovine) coupled to succinylated aminododecyl-cellulose	Merck	* ^a ,b		Trypsin	Ligand density 15–20 $\mu mol ml^{-1}$	Trypsin inhibitor

Agarose	Matrix Gel PBA	Amicon, Grace Pharmacia o,b		Phenyl boronate	
	Protein A-Sepharose CL-4B		60–140	Protein A	IgG-type antibodies, immune complexes
	Con A-Sepharose	Pharmacia o,b	60–140	Concanavalin A	Glycoproteins, polysaccharides, glycolipids with α -D-mannopyranose or α -D-glucopyranose
Lentil lectin-Sepharose 4B		Pharmacia o,b	60–140	Lentil lectin	Glycoproteins with α -D-glucose or α -D-mannose
Wheat germ lectin-Sepharose 6MB		Pharmacia o,b	45–165	Wheat germ lectin	Cells, glycoproteins and polysaccharides with N-acetylglucosamine
Poly(U)-Sepharose 4B	Pharmacia o,b		60–140	Polyuridylic acid	Messenger RNA, reverse transcriptase, interferon m-RNA binding proteins, poly(A) binding RNA
Poly(A)-Sepharose 4B	Pharmacia o,b		60–140	Polyadenylic acid	Plasmogen, r-RNA, DNA
Lysine-Sepharose 4B	Pharmacia o,b		60–140	L-Lysine	Enzymes requiring adenylyl-containing cofactors, albumin, interferon NAD ⁺ -dependent dehydrogenases, ATP-dependent kinases
Blue Sepharose CL-6B	Pharmacia o,b		45–165	Cibacron Blue F3G-A	NADP ⁺ -dependent dehydrogenases and other proteins
<i>S'</i> -AMP-Sepharose 4B				<i>S'</i> -AMP on C-6 spacer	
<i>2'S</i> -ADP-Sepharose 4B				<i>2'S</i> -ADP on C-6 spacer	Glucose-6-phosphate dehydrogenase
Cross-linked agarose	Affi-Gel Blue	Bio Rad o,b	80–150 150–130	Cibacron Blue F3GA	0.4 mg ml ⁻¹
	DEAE-Affi-Gel Blue	Bio-Rad o,b		DEAE and Cibacron Blue F3GA	Enzymes, albumin, interferon
	CM-Affi-Gel Blue	Bio-Rad o,b		CM and Cibacron Blue F3GA	All serum proteins except IgG and transferrin
					Albumin, serum protease and complement

(Continued on p 256)

TABLE 6 (continued)

Type	Name	Supplier	Form	$d\mu/\mu\text{m}$	Activator group or ligand	Binding capacity	Ligand specificity
Affigel 401	Bio-Rad	o,b	-SH				Sulphydryl, mercury
Affigel 501	Bio-Rad	o,b	-Hg				Sulphydryl
Affigel 601	Bio-Rad	o,b	Phenylboronic acid	130 $\mu\text{mole ml}^{-1}$	Sorbitol		cis-Diol
Cross-linked agarose	Affi-Gel heparin	Bio-Rad	o,b	Heparin	Human antithrombin III	1.2 mg ml^{-1}	Various proteins
Polyacrylamide	Affi-Gel calmodulin	Bio-Rad	o,b		Calmodulin	0.2 mg ml^{-1}	Calcium-dependent enzymes
Cross-linked acrylic polymer	Affi-Gel gelatin	Bio-Rad	o,b		Gelatin	Human plasma fibronectin	Fibronectin
Polyacrylamide	Affi-Gel Con A	Bio-Rad	o,b		Concanavalin A	1 mg ml^{-1}	Glycoproteins, glycopeptides, saccharides
Cross-linked agarose	Affi-Gel 731	Bio-Rad	o,b		Polyethyleneimine	Thyroglobulin 10 mg ml^{-1}	Membranes
	Affi-Gel cell sorting beads, anti-mouse anti-rabbit anti-TTC	Bio-Rad	o,b,c	250 ± 50	Antibodies		B-cells/T-cells
Cross-linked agarose	Glyco Gel	Pierce	*,b	45–165	3-Aminobenzeneboronic acid		cis-Diols
	Detoxi Gel	Pierce	*,b	45–165			
	Detoxi Gel	Pierce	*,b	45–165			
	Extract-Gel D	Pierce	*,b	45–165			
	Immobilized Avidin	Pierce	*,b	45–165	Avidin	SDS 80 mg ml^{-1} , Triton X-100 25 mg ml^{-1}	Endotoxins (lipopolysaccharides) Detergents
	Immobilized Immobiotin	Pierce	*,b	45–165	Immobiotin on spacer		Biotin-containing proteins
	Immobilized D-Biotin	Pierce	*,b	45–165	D-Biotin on spacer	1 mg ml^{-1}	Avidin and derivatives
	Immobilized protein A	Pierce	*,b	45–165	Protein A	2 mg ml^{-1}	Avidin, biotin-binding proteins
						Human IgG 13–15 mg ml^{-1}	Antibodies

Immobilized papain	Pierce	*,b	45–165	Loading 250 µg ml ⁻¹	Protein digestion
Immobilized pepsin	Pierce	*,b	45–165	Loading 2–3 mg ml ⁻¹	Protein digestion
Immobilized N-acetyl-D-glucosamine	Pierce	*,b	45–165	Wheat germ lectin 5–10 mg ml ⁻¹	Lectins, proteins with binding specificity for that carbohydrate
Immobilized N-acetyl-D-galactosamine	Pierce	*,b	45–165	Soybean lectin 3–5 mg ml ⁻¹	Lectins, proteins with binding specificity for that carbohydrate
Immobilized L-fucose	Pierce	*,b	45–165	Lolu lectin 3–5 mg ml ⁻¹	Lectins, proteins with binding specificity for that carbohydrate
Immobilized D-mannose	Pierce	*,b	45–165	Vicia fabia lectin 3–5 mg ml ⁻¹	Lectins, proteins with binding specificity for that carbohydrate
Immobilized lactose II	Pierce	*,b	45–165	Castor bean lectins 8–10 mg ml ⁻¹	Lectins, proteins with binding specificity for that carbohydrate
Immobilized D-galactose	Pierce	*,b	45–165	Castor bean lectins 8–9 mg ml ⁻¹	Lectins, proteins with binding specificity for that carbohydrate
Immobilized β-D-glucose	Pierce	*,b	45–165	Con A 8–10 mg ml ⁻¹	Con A, proteins with β-D-Glu specificity
Immobilized N-acetyl-D,L-homocysteine	Pierce	*,b	45–165	Loading 23–27 µmole ml ⁻¹ SH	Polynucleotides, enzymes
Immobilized L-alanyl-L-alanine	Pierce	*,b	45–165	Elastase 2–3 mg ml ⁻¹	Elastase
Immobilized p-aminobenzamidine	Pierce	*,b	45–165	Trypsin 7 mg ml ⁻¹	Trypsin, kinases, other proteins
Immobilized p-aminophenylphosphonic acid	Pierce	*,b	45–165	Calf intestinal alkaline phosphatase 0.5–1 mg ml ⁻¹	Phosphatases
Immobilized (2)-Aminoethyldihydrogen-phosphate	Pierce	*,b	45–165	Loading 33–35 µmole ml ⁻¹	C-reactive protein

(Continued on p. 258)

TABLE 6 (continued)

Type	Name	Supplier	Form	$d\mu/\mu m$	Activator group or ligand	Binding capacity	Ligand specificity
Immobilized <i>p</i> -Amino-phenylphosphoryl-choline	Pierce	* ^a ,b	45–165		Human CRP 3–5 mg ml ⁻¹		C-reactive protein
Immobilized <i>p</i> -chloro-mercuribenzoate	Pierce	* ^a ,b	45–165		Haemoglobin 40 mg ml ⁻¹		Sulphydryl-containing proteins
Immobilized Cibacron Blue F3GA	Pierce	* ^a ,b	45–165		Human serum albumin 18 mg ml ⁻¹		Proteins
Immobilized deoxycholic acid	Pierce	* ^a ,b	45–165		HSA 1 mg ml ⁻¹		Membrane molecules
Immobilized dextran sulphate	Pierce	* ^a ,b	45–165		Loading 0.5–0.6 mg ml ⁻¹		Special antigens
Immobilized diaminodipropylamine	Pierce	* ^a ,b	45–165		Loading 16–20 μ mole ml ⁻¹		-COOH (carboxymide method)
Immobilized 17-estradiol-17-hemsuccinate	Pierce	* ^a ,b	45–165				Estradiol receptors
Immobilized fetuin	Pierce	* ^a ,b	45–165		Loading 1–2 mg ml ⁻¹		Lectins
Immobilized gelatin	Pierce	* ^a ,b	45–165		Human plasma fibronection		Fibronectins
Immobilized glycyl-L-tyrosylazobenzylsuccinic acid	Pierce	* ^a ,b	45–165		1 mg ml ⁻¹		Carboxypeptidases
Immobilized heparin	Pierce	* ^a ,b	45–165		Carboxypeptidase 1 mg ml ⁻¹		
Immobilized histamine	Pierce	* ^a ,b	45–165				
Immobilized iminodiacetic acid	Pierce	* ^a ,b	45–165				
Immobilized methotrexate	Pierce	* ^a ,b	45–165		Loading 0.4–0.5 mg ml ⁻¹		Various proteins (e.g., RNA polymerase)
Immobilized pepstatin	Pierce	* ^a ,b	45–165		Loading 30–40 μ mole ml ⁻¹		Haeme-containing proteins, inorganic cation chelates bind several glycoproteins and lipoproteins, dihydrofolate reductase
							(Acid) proteases
							Hog pepsin 1–2 mg ml ⁻¹

				Chymotrypsin 3 mg ml ⁻¹	Proteases
Immobilized (N ^z -CBZ)-D-phenylalanine	Pierce	* ,b	45-165		Several proteins
Immobilized poly-(L-lysine)	Pierce	* ,b	45-165		Proteins (e.g., dehydrogenases)
Immobilized Procion Red HE3B	Pierce	* ,b	45-165	Human serum albumin 11-13 mg ml ⁻¹	Several proteins
Immobilized protamine	Pierce	* ,b	45-165	Calf thymus DNA 50 µg ml ⁻¹	N-Acetylneurameric acid-containing molecules
Immobilized serotonin	Pierce	* ,b	45-165	Ferum 1 mg ml ⁻¹	Proteins, RNA
Immobilized spermine	Pierce	* ,b	45-165	Loading 18-22 µmole ml ⁻¹	
Immobilized L-(+)-tartric acid	Pierce	* ,b	45-165	0-5-1 mg ml ⁻¹	Prostatic acid, phosphatase
Immobilized tri(2-carboxymethyl)-ethylenediamine	Pierce	* ,b	45-165	Copper 40-45 µg ml ⁻¹	Cation chelates bind proteins
Dryptophan methyl ester	Pierce	* ,b	45-165	α-Chymotrypsin 2-3 mg ml ⁻¹	Chymotrypsin, carboxypeptidases
Cross-linked dextran	Pierce	* ,b	45-165		Peptides and proteins with exponated histidine or cysteine
Polyacrylamide					Lectins
Immobilized minodiacetic acid	Pierce	* ,b	45-165		Lectins, galactosidases
Immobilized lactose	Pierce	o,b	45-165		Lectins, glucosidases
Immobilized melibiose	Pierce	o,b	45-165		
Immobilized cellulose	Pierce	o,b	45-165		
Immobilized boronic acid	Pierce	o,b	45-165		
Immobilized tris-(carboxymethyl)-ethylenediamine	Pierce	* ,b	32-63		
Immobilized immunodi-acetic acid	Pierce	* ,b	32-63		
Cibacron Blue F3GA	Pierce	* ,b	32-63		
Immobilized heparin					

(Continued on p. 260)

TABLE 6 (*continued*)

Type	Name	Supplier	Form	Activator group or ligand	Binding capacity	Ligand specificity
Polyacryl-amide-agarose gel	Con A-Ultrogel LcA-Ultrogel	IBF/LKB * ^a ,b	100–140 100–140	Ovalbumin ≥ 0.6 mg ml ⁻¹	Glc/Man Man/Glc	
		IBF/LKB * ^a ,b	100–140	Thyroglobulin ≥ 2 mg ml ⁻¹		
	WGA-Ultrogel	IBF/LKB * ^a ,b	100–140	Ovomucoid ≥ 0.35 mg ml ⁻¹	Glc-NAc/D-Glc-chtobose	
	HpA-Ultrogel	IBF/LKB * ^a ,b	100–140	A ₁ ⁺ human erythrocytes 4.5 · 10 ⁶ ml ⁻¹	Gal-NAc	
	PNA-Ultrogel	IBF/LKB * ^a ,b	100–140	Asialofetuin ≥ 0.4 mg ml ⁻¹	Gal/Lact	
	Protein A-Ultrogel	IBF/LKB * ^a ,b	100–140	Human IgG 10 mg ml ⁻¹	Immunoglobulins G	
	Calmodulin-Ultrogel	IBF/LKB * ^a ,b	100–140	Polylysine 0.8 mg ml ⁻¹	Calcium-dependent enzymes	
	Avidin-Ultrogel A4R	IBF/LKB * ^a ,b	60–140	Biotinylated albumin 1 mg ml ⁻¹	Biotin	
	Gelatin-Ultrogel ss DNA-Ultrogel A4R	IBF/LKB * ^a ,b	60–140	Human fibronectin 1 mg ml ⁻¹	Cell adhesion factors	
	Acriflavine-Ultrogel A4R	IBF/LKB * ^a ,b	60–140	Prothamine sulphate 5–10 mg ml ⁻¹	DNA-dependent or -containing proteins	
	Phospho-Ultrogel A6R	IBF/LKB * ^a ,b	60–140	Loading 15–20 μmole ml ⁻¹	Aromatic molecules (nucleic acids, dyes)	
	Blue-Ultrogel A4R	IBF/LKB * ^a ,b	60–140	Loading 100 μmole ml ⁻¹	Phosphatases	
	Heparin-Ultrogel A4R	IBF/LKB * ^a ,b	60–140	acidic groups Human albumin 12 mg ml ⁻¹	Various proteins	
	Oligo(dT) ₈ -Trisacryl M	IBF/LKB * ^a ,b	60–140	Human antithrombin III	Various proteins	
Acrylic polymer	Blue-Trisacryl M	IBF/LKB * ^a ,b	40–80	1.8–2.8 mg ml ⁻¹ Poly(A)	Eucaryonic m-RNA	
				0.15 mg ml ⁻¹		
				Human albumin 10–15 mg ml ⁻¹	Various proteins	

does not provide sufficient purity and thus a sequence of modes is applied in the appropriate manner.

Resolution apart, LC phase systems have very different loadability characteristics. Again, therefore, the selection of an LC phase system is dictated by the maximization of the chromatographic resolution times the maximum sample input, as shown in eqn. 6.

The characteristics of LC phase systems, together with other relevant aspects, are briefly discussed below.

6.1. *Size exclusion chromatography (SEC)^{23,24}*

SEC has the lowest resolution of all LC modes, which can be attributed to the limited separation volume of SEC columns. Hence, SEC is suitable for the fractionation of sample mixtures according to molecular size and shape of solutes, and is the method of choice for desalting. It should be noted that SEC columns cannot be loaded with large feed volumes. The maximum feed volume while maintaining maximum resolution under analytical conditions is about 1–2% of the total column volume²⁴. One advantage of SEC is that the solutes are eluted in a short and predictable time interval.

6.2. *Adsorption chromatography*

Both normal- and reversed-phase chromatography (RPC) are methods for achieving high resolution. In comparison with RPC, normal-phase chromatography with native silica or other adsorbents offers several advantages, *e.g.*, reasonably priced packings, application of a broad range of solvents as eluents, easy removal of solvents by evaporation after fractionation, high solubility of sample mixture components, application of high flow-rates owing to the low viscosity of the eluents and analysis of fractions by thin-layer chromatography. Drawbacks are the relatively long calibration periods of normal-phase systems²⁰ and surface fouling by strong, irreversible adsorption of polar contaminants. The latter can be prevented by employing a pre-column or by using adsorbents with moderate specific surface areas ($a_s \sim 100 \text{ m}^2 \text{ g}^{-1}$).

RPC is universally applicable to polar, hydrophobic and ionized solutes. Regeneration and equilibration of phase systems is faster than for plain silica. The use of aqueous or aqueous–organic eluents causes higher column pressure drops under comparable conditions than do the low-viscosity eluents in normal-phase chromatography, making the isolation of purified products more tedious.

Reversed-phase gradient LC can also be applied for the isolation of peptides and polypeptides in acidic hydro–organic eluents of low ionic strength²⁵. The solutes are separated according to their hydrophobic or hydrophilic character. Problems often arise in the maintenance of the biological activity of biopolymers.

Hydrophobic interaction chromatography is a more suitable method of protein isolation with regard to the preservation of biological activity, applying a descending salt gradient at neutral pH²⁶.

6.3. Ion-exchange chromatography (IEC)

IEC offers a high selectivity and resolution when a pH or salt gradient is applied. It has been found particularly efficient in the isolation of proteins²⁷. Ion-exchange columns have a high loadability and are preferentially employed during the initial purification stages when large amounts of sample mixtures are handled. The loadability is of the order of 100 mg/g of ion exchanger and is dependent on the surface area of the packing.

6.4. Affinity chromatography (AC)²⁸

Compared with the other LC modes, AC possesses the highest selectivity and flexibility towards biospecific solutes. For example, immunoadsorbents with coupled monoclonal antibodies have an exceptionally high biospecific recognition²⁹. The flexibility is based on the availability of activated affinity media for the purpose of binding specific ligands; the specificity can be further controlled by the elution conditions.

7 FUTURE PROSPECTS

With a few exceptions, the tailor-made manufacture of packings for preparative and process chromatography has as yet received very little attention. This situation, however, is bound to change radically in the near future as a result of the dramatic increase in chromatographic separation methods in the areas of biotechnology and gene technology. Together with the improvements in biotechnological processes, research and development in packings will focus on three major topics:

- (i) the synthesis of better defined, more reproducible and biocompatible supports that meet the required criteria,
- (ii) the bonding chemistry in the synthesis of a limited number of well characterized and stable packings that offer high flexibility by further modification to multi-mode chromatography; and
- (iii) the synthesis of highly biospecific packings for the selective recognition and isolation of biologically active solutes

8 LIST OF SUPPLIERS

Amicon Corporation, 17 Cherry Hill Drive, Danvers, MA 01923, U.S.A.

J. T. Baker, 222 Red School Lane, Phillipsburg, NJ 08865, U.S.A.

Baker Chemikalien, Postfach 1661, 6080 Gross-Gerau, F.R.G.

Bio-Rad Laboratories, 2200 Wright Avenue, Richmond, CA 94804, U.S.A.

Bio-Rad Laboratories GmbH, Dachauer Str. 364 + 511, Box 50-0167, 8000 Munich, F.R.G.

Grace Industrial Chemicals Inc., Amicon Europe, Av. de Montchorsi 35, CH-1001 Lausanne, Switzerland

Hamilton Co., Reno, NV, U.S.A.

Hamilton Deutschland GmbH, Otto-Röhm-Str. 74, 6100 Darmstadt, F.R.G.

Reactifs IBF, Société Chimique Pointet Girard, 35 Avenue Jean-Jourès, F-92390

Villeneuve-La-Garenne, France
ICN Biomedicals GmbH, Postfach 369, 2440 Eschwege, F.R.G.
Kali Chemie AG, Hans-Böckler-Allee 20, 3000 Hannover 1, F.R.G.
LKB Produkter AB, Box 305, S-16126 Bromma, Sweden
LKB Instruments Inc., 9319 Gaither Road, Gaithersburg, MD 20877, U.S.A.
Macherey-Nagel & Co., Neumann-Neander Str. 6-8, Postf. 307, 5160 Düren, F.R.G.
E. Merck, Frankfurter Strasse, 250, 6100 Darmstadt, F.R.G.
E M. Science, 111 Woodcrest Rd., Cherry Hill, NJ 08034-0395, U.S.A.
Millipore Waters Chromatography Div., 34 Maple Street, Milford, MA 01757,
U.S.A.
Millipore Water Chromatographie, Hauptstr. 71-79, 7236 Eschborn, F.R.G.
Pharmacia Fine Chemicals AB, S-75182 Uppsala, Sweden
Pierce Chemical Co., P.O. Box 117, Rockford, IL 61105, U.S.A.
The Separations Group, Inc., 17434 Mojave, P.O. Box 867, Hesperia, CA 92345,
U.S.A.
Synchrom Inc., P.O. Box 110, Linden, IN 47955, U.S.A.
Toyo Soda Manufacturing Co., Ltd., 1-7-7 Akasaka, Minato-ku, Tokyo, Japan
Whatman Chemical Separation Inc., 9 Bridgewell Place, Clifton, NJ 07014, U.S.A.
Whatman Chemical Separations Ltd., Springfield Mill, Maidstone, Kent ME12 2LE,
U.K.

9 SUMMARY

Although the theoretical treatment of chromatographic processes on a preparative scale provides guidelines to the extent to which packing and stationary phase properties affect the target quantities such as sample input, throughput and resolution times sample input, a series of additional criteria were established to judge the quality of a packing in preparative column liquid chromatography. These include bed stability and flow resistance, chemical resistance and purity, solute accessibility, mass and biological recovery, fouling, regeneration and cost. Applying these criteria, the relative importance of physical and chemical structure parameters of packings and stationary phases was assessed. Commercial packings with mean particle diameters $d_p > 20 \mu\text{m}$ were listed for adsorption, size exclusion, ion-exchange and affinity chromatography. An analysis of the characteristic features of phase systems showed that adsorption media offer a high selectivity combined with adequate loadability, whereas ion exchangers and affinity media were best suited for biospecific solutes, particularly biopolymers, which can be attributed to their high selectivity and loadability.

REFERENCES

- 1 A W J de Jong, J. C Kraak, H Poppe and F Nooitgedacht, *J Chromatogr*, 193 (1980) 181;
A W J de Jong, H Poppe and J. C Kraak, *J Chromatogr*, 209 (1981) 432.
- 2 A Wehrli, in H Engelhardt (Editor), *Practice of High Performance Liquid Chromatography*, Springer-Verlag, Heidelberg, 1986, pp 109-142
- 3 A Wehrli, U Hermann and J. F. K. Huber, *J Chromatogr*, 125 (1976) 59
- 4 J J Kipling, *Adsorption from Solutions of Non-electrolytes*, Academic Press, London, 1965
- 5 H Colin, G Lowry and J Cazes, *Int Lab*, Oct (1985) 78

- 6 A Wehrli, *Fresenius Z Anal Chem.*, 277 (1975) 289
- 7 B Coq, G Cretier and J L Rocca, *J Chromatogr*, 186 (1979) 457.
- 8 P A. Bristow and J H Knox, *Chromatographia*, 10 (1977) 279
- 9 J C Janson, in A Fiechter (Editor), *Advances in Biochemical Engineering*, Vol. 25, *Chromatography*, Springer-Verlag, Heidelberg, 1982, pp 44-97
- 10 K K Unger, G Jilge, J N. Kinkel and M T W. Hearn, *J Chromatogr*, 359 (1986) 61
- 11 M T W Hearn, A. N Hodder and M -I Aguilar, *J Chromatogr*, 327 (1985) 47.
- 12 C T Wehr, *Methods Enzymol*, 104c (1984) 133
- 13 K Unger, *Porous Silica*, Elsevier, Amsterdam, 1979, pp 15-40 and 147-162
- 14 K. K Unger, *Packings and Stationary Phases in Chromatographic Techniques*, Marcel Dekker, New York, in preparation
- 15 G Guiochon, in C Horvath (Editor), *High Performance Liquid Chromatography—Advances and Perspectives*, Academic Press, New York, 1980, pp 1-54
- 16 K K Unger, B Anspach and H Giesche, *J. Pharm Biomed Anal.*, 2 (1984) 139.
- 17 R E. Majors, *J Chromatogr. Sci*, 15 (1977) 334
- 18 R E Majors, in C Horvath (Editor), *High Performance Liquid Chromatography—Advances and Perspectives*, Academic Press, New York, 1980, pp 76-108
- 19 K. Unger, *Porous Silica*, Elsevier, Amsterdam, 1979
- 20 H. Engelhardt and H Elgass, in C Horvath (Editor), *High Performance Liquid Chromatography—Advances and Perspectives*, Academic Press, New York, 1980, pp 57-108.
- 21 K K Unger, unpublished results
- 22 *Scale up to Process Chromatography*, Brochure, Pharmacia, Uppsala, 1985
- 23 W W Yau, J J Kirkland and D D Bly, *Modern Size Exclusion Liquid Chromatography*, Wiley-Interscience, New York, 1979
- 24 K Unger, *Methods Enzymol*, 104c (1984) 154
- 25 M T W Hearn, in C. Horvath, *High Performance Liquid Chromatography—Advances and Perspectives*, Vol 3, Academic Press, New York, 1983, pp 87-155
- 26 Sh. Shaltiel, *Methods Enzymol*, 104c (1984) 69
- 27 F. Regnier, *Methods Enzymol*, 104c (1984) 170.
- 28 H Schott, *Affinity Chromatography*, Marcel Dekker, New York, 1984.
- 29 S J. Tarnowsky, paper presented at the *5th International Symposium on HPLC of Proteins, Peptides, and Polynucleotides*, Toronto, 1-6th November 1985, paper 702